Mylan/Gilead, AbbVie/MPP boost access to HIV medicines
This article was originally published in Scrip
Executive Summary
Access to Gilead Sciences's next-generation HIV medicines and pediatric formulations of AbbVie's biggest-selling antiviral therapy will increase in developing countries under new agreements with commercial and nonprofit partners, Mylan and the Medicines Patent Pool (MPP).
You may also be interested in...
Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos
Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.
Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos
Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.